Morgan Stanley
OACC icon

Morgan Stanley’s Oaktree Acquisition Corp III Life Sciences OACC Stock Holding History

Morgan Stanley’s Portfolio OACC Stock Details OACC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$610 Sell
57
-18
-24% -$192 ﹤0.01% 7609
2026
Q1 		$794 Buy
75
+21
+39% +$224 ﹤0.01% 7480
2025
Q4 		$571 Buy
54
+53
+5,300% +$561 ﹤0.01% 7483
2025
Q3 		$11 Sell
1
-55
-98% -$575 ﹤0.01% 8097
2025
Q2 		$585 Buy
56
+3
+6% +$31 ﹤0.01% 7417
2025
Q1 		$542 Buy
+53
New +$532 ﹤0.01% 7358

Other funds holding OACC

AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.37B AUM 26.91% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.03B AUM 47.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BGGS
Boussard & Gavaudan Gestion SAS Paris, France $1.99B AUM
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley's OACC Position: Q2 2026 in Review

Morgan Stanley reduced its Oaktree Acquisition Corp III Life Sciences (OACC) stake by 24% in Q2 2026, selling an estimated $192 and leaving 57 shares worth $610. The position accounts for ﹤0.01% of the portfolio, ranked #7609.

Morgan Stanley first reported a position in OACC in Q1 2025 and has held it in 6 quarters since. The position peaked at $794 in Q1 2026. 51 funds tracked by Wall St. Rank hold OACC as of Q2 2026.

  • Morgan Stanley held 57 shares of Oaktree Acquisition Corp III Life Sciences worth $610 as of Q2 2026.
  • Morgan Stanley sold 18 Oaktree Acquisition Corp III Life Sciences shares in Q2 2026, an estimated $192.
  • Oaktree Acquisition Corp III Life Sciences made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7609 holding.
  • Morgan Stanley first reported a position in Oaktree Acquisition Corp III Life Sciences in Q1 2025 and has held it in 6 quarters since.
  • Morgan Stanley's Oaktree Acquisition Corp III Life Sciences position peaked at $794 in Q1 2026.
  • 51 funds tracked by Wall St. Rank held Oaktree Acquisition Corp III Life Sciences as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.